ELOXX PHARMACEUTICALS, INC.

(ELOX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/20/2022 05/23/2022 05/24/2022 05/25/2022 05/26/2022 Date
0.336(c) 0.3449(c) 0.335(c) 0.3265(c) 0.31(c) Last
151 682 110 052 87 934 448 658 261 883 Volume
-3.75% +2.65% -2.87% -2.54% -5.05% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1,75 M - -
Net income 2022 -43,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,65x
Yield 2022 -
Sales 2023 1,63 M - -
Net income 2023 -54,7 M - -
Net Debt 2023 - - -
P/E ratio 2023 -0,58x
Yield 2023 -
Capitalization 26,9 M 26,9 M -
Capi. / Sales 2022 15,3x
Capi. / Sales 2023 16,5x
Nbr of Employees 28
Free-Float 87,3%
More Financials
Company
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing ribonucleic acid (RNA)-modulating drug candidates, each designed to be a eukaryotic ribosomal selective glycoside (ERSG), formulated to treat rare and ultra-rare premature stop codon diseases. The Company's lead product candidate, ELX-02, is a small molecule designed to restore production of full-length... 
More about the company
Ratings of Eloxx Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about ELOXX PHARMACEUTICALS, INC.
05/23Piper Sandler Adjusts Eloxx Pharmaceuticals' Price Target to $1.50 from $4, Keeps Overw..
MT
05/10Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Pr..
GL
05/10Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Pr..
AQ
05/09HC Wainwright Trims Eloxx Pharmaceuticals Price Target to $0.5 From $1, Maintains Neutr..
MT
05/06ELOXX PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
05/06Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
04/11ELOXX PHARMACEUTICALS : April 2022 Investor Presentation
PU
04/07Top Premarket Decliners
MT
04/04ELOXX PHARMACEUTICALS : Reports Fourth Quarter 2021 Financial and Operating Results and Pr..
PU
03/31Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and P..
GL
03/31NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
03/30ELOXX PHARMACEUTICALS, INC. MANAGEMENT'S Discussion and analysis of financial conditio..
AQ
03/30Eloxx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 3..
CI
03/30Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of..
GL
03/30Eloxx Pharmaceuticals, Inc. Announces New Development Program for ELX-02 for the Treatm..
CI
More news
News in other languages on ELOXX PHARMACEUTICALS, INC.
05/06Eloxx Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 ..
03/30Eloxx Pharmaceuticals, Inc. annonce ses résultats pour l'année complète se terminant le..
03/30Eloxx Pharmaceuticals, Inc. annonce un nouveau programme de développement pour ELX-02 p..
03/30Eloxx Pharmaceuticals, Inc. Le vérificateur soulève un doute sur la continuité de l'exp..
03/29Eloxx Pharmaceuticals obtient un financement pouvant atteindre environ 16 millions de d..
More news
Analyst Recommendations on ELOXX PHARMACEUTICALS, INC.
More recommendations
Chart ELOXX PHARMACEUTICALS, INC.
Duration : Period :
Eloxx Pharmaceuticals, Inc. Technical Analysis Chart | ELOX | US29014R1032 | MarketScreener
Technical analysis trends ELOXX PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,31 $
Average target price 2,25 $
Spread / Average Target 626%
EPS Revisions
Managers and Directors
Sumit Aggarwal President, Chief Executive Officer & Director
Daniel E. Geffken Chief Financial & Accounting Officer
Tomer Kariv Chairman
Vijay Modur Head-Research & Development
Ali Hariri Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ELOXX PHARMACEUTICALS, INC.-56.10%27
GILEAD SCIENCES, INC.-11.21%80 866
REGENERON PHARMACEUTICALS, INC.8.22%73 638
VERTEX PHARMACEUTICALS22.79%68 965
BIONTECH SE-38.65%38 433
WUXI APPTEC CO., LTD.-25.70%37 870